Failure to treat early and appropriately can lead to fatal outcomes for these patients.1,2* The impact of delayed appropriate therapy is depicted below:
The importance of early appropriate therapy in serious infections
CRE
P. aeruginosa
ESBL
†Compared with receipt of timely appropriate therapy.1
‡Defined as no receipt of antibiotic(s) with relevant microbiological activity on or within 2 days of index date.1
§28-day mortality among 205 patients with BSIs caused by carbapenemase-producing K. pneumoniae (KPC and/or VIM).3
¶The epidemiological staging system for measuring the extent of CRE spread across healthcare facilities was developed in 2010.4
**National experts representing all 37 invited European countries completed the 2018 capacity survey.4
††30-day mortality rate among patients with P. aeruginosa bacteraemia who received ‘delayed effective antimicrobial therapy’.6
‡‡Combined resistance to ≥3 of the following: piperacillin/tazobactam, fluoroquinolones, ceftazidime, aminoglycosides and carbapenems.9
§§30-day mortality among 909 patients with BSIs caused by ESBL-producing K. pneumoniae (n=222) and E. coli (n=687).8
¶¶Based on four patient-level simulation models used to evaluate the cost-effectiveness of adding ZAVICEFTA as a treatment for cIAI, cUTI and HAP/VAP to a hospital formulary in Italy. The model and results may vary between markets.11–13
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Dette nettstedet er kun for helsepersonell.
Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.
Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.